Core Viewpoint - Supernus Pharmaceuticals has announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition of Sage Therapeutics, indicating progress towards completing the merger [1][3]. Acquisition Details - Supernus and Sage entered into a Merger Agreement on June 13, 2025, with the necessary premerger notifications filed with regulatory authorities shortly thereafter [2]. - The Offer to Purchase for Sage's outstanding shares is set at $8.50 per share in cash, plus a contingent value right (CVR) that could yield up to an additional $3.50 per share based on specific milestones [4]. Contingent Value Rights (CVR) - The CVR includes milestone payments contingent on the commercial success of the product ZURZUVAE, with payments structured as follows: - $0.50 per CVR upon the first commercial sale in Japan after regulatory approval by June 30, 2026 [5]. - $1.00 per CVR if net sales of ZURZUVAE reach $250 million in the U.S. by December 31, 2027 [6]. - $1.00 per CVR if net sales reach $300 million in the U.S. by December 31, 2028 [7]. - $1.00 per CVR if net sales reach $375 million in the U.S. by December 31, 2030 [8]. - The total maximum payout for each CVR is capped at $3.50, with no guarantee that any payments will be made [9][10]. Merger Completion - Upon completion of the Offer, Supernus plans to merge its wholly owned subsidiary with Sage, resulting in Sage becoming a wholly owned subsidiary of Supernus [11]. - Shares not purchased in the Offer will be converted into the right to receive the Offer Price, and Sage's shares will be delisted from NASDAQ [11]. Advisory Information - Moelis & Company LLC is the exclusive financial advisor for Supernus, while Goldman Sachs & Co. LLC serves as the exclusive financial advisor for Sage [12].

Core Insights - ParaZero Technologies Ltd. has successfully completed a field trial for an enhanced variant of its DefendAir system, which expands the company's drone defense capabilities [1][2] Company Developments - The trial tested a new stationary net turret launcher system that provides 360-degree perimeter defense against hostile drones, featuring an advanced optical detection and tracking system for fully autonomous operation [2] - The enhanced net launcher allows for a larger net deployment, improving effectiveness against faster and larger drone threats, aimed at securing high-value sites such as critical infrastructure and government buildings [3] - CEO Ariel Alon emphasized the company's commitment to building an integrated, layered defense ecosystem to address evolving aerial threats [5] Market Context - The global anti-drone market was valued at $2.4 billion in 2024 and is projected to grow from $3.1 billion in 2025 to $12.24 billion by 2032, with a compound annual growth rate (CAGR) of 21.62% during the forecast period [4] - ParaZero's expansion of the DefendAir product line, alongside its portable net gun configuration, strengthens its position in the counter-unmanned aerial systems (C-UAS) market, offering versatile solutions for defense and homeland security sectors [4]

BATON ROUGE, La., July 28, 2025 (GLOBE NEWSWIRE) -- Business First Bancshares, Inc. (NASDAQ: BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended June 30, 2025. Business First reported net income available to common shareholders of $20.8 million or $0.70 per diluted common share, increases of $1.6 million and $0.05, respectively, compared to the linked quarter ended March 31, 2025. On a non-GAAP basis, core net income for the quarter ended June 30, 20 ...

NEW BRUNSWICK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- DatChat, Inc. (Nasdaq: DATS) (“DatChat” or the “Company”), a secure messaging and social media company, today announced that the Canadian Patent Office has granted Canadian Patent No. 3,149,004, titled “Systems And Methods Of Transforming Electronic Content.” “We are continuing to build our global intellectual property portfolio covering our advanced digital privacy and other technologies. These patents are extremely important as we prepare for the worl ...

eQ Plc Investor news28 July 2025, at 3:15 p.m. eQ Plc will publish its January-June 2025 half year financial report on Tuesday 5 August 2025 at around 8:00 a.m. eQ will present the result to press, investors and analysts in a press conference to be held on 5 August 2025 at 11:30 a.m. The press conference will held at eQ's head office in Helsinki, address Aleksanterinkatu 19, 5th floor, 00100 Helsinki and it is also possible to participate via webcast. The webcast participation requires a registration. The ...

Core Insights - Brera Holdings PLC has become the second multi-club ownership (MCO) entity in Italy's Serie B League, acquiring SS Juve Stabia, while City Football Group holds Palermo FC, indicating a competitive landscape in the soccer market [2][3] Group 1: Company Overview - Brera Holdings is an Ireland-based international holding company focused on expanding its portfolio of men's and women's football clubs through a multi-club ownership strategy [2][7] - The company aims to create opportunities for tournament prizes, sponsorships, and professional consulting services, building on the legacy of Brera FC, which it acquired in 2022 [7] Group 2: Recent Developments - Brera's portfolio club, SS Juve Stabia, recorded a 245% increase in market value over the 2024-25 season, reaching a valuation of US$32 million [4][6] - The squad value of Juve Stabia surged from US$9.3 million after promotion from Serie C to Serie B, driven by strong on-field performance [5] Group 3: Strategic Expansion - Brera has expanded its reach into Africa by establishing Brera Tchumene FC in Mozambique, which quickly rose to the First Division [8] - The company has made strategic investments in various clubs, including a 90% stake in Fudbalski Klub Akademija Pandev in North Macedonia and a joint stock company for Tiverija Strumica [8] Group 4: Ownership and Control - Brera executed an agreement to acquire a majority stake in SS Juve Stabia, concluding the acquisition process on June 20, 2025, marking a significant expansion of its MCO model [9]

The Company will Develop a New Product to Enable Advanced Tactical Video and Edge Computing Capabilities Rehovot, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in video and artificial intelligence (“AI”) - based edge computing technology, today announced that it has received a $144,000 order. The order, placed by a customer in the defense industry, is for the design and development of an advanced tactical video and AI-based p ...

Miami, FL, July 28, 2025 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital energy and infrastructure company, today announced the closing on July 25, 2025 of its upsized offering of 0.00% convertible senior notes due 2032 (the “notes”). The aggregate principal amount of the notes sold in the offering was $950 million. MARA also granted the initial purchasers an option to purchase up to an additional $200 million aggregate principal amount of the notes within ...

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was shown to internalize and digest amyloid and α-synuclein proteins in vitro and to improve CSF levels of amyloid, α-synuclein, and p-tau in Phase 1 patients in a largely dose-dependent manner. Troculeucel identifies and eliminates auto-activated T cells without disrupting resting T cells in vitr ...

Core Viewpoint - IMUNON, Inc. announced a 15% stock dividend, reflecting the company's confidence in its Phase 3 clinical study and long-term growth potential, while also demonstrating dedication to its shareholders [1][3]. Group 1: Stock Dividend Details - The stock dividend program will distribute approximately 448,000 additional shares of IMUNON common stock for each share held, payable to holders of record as of August 7, 2025, with distribution expected on August 21, 2025 [2]. - Stockholders will not need to take any action to receive the dividend, as additional shares will be credited to their accounts [2]. Group 2: Company Strategy and Clinical Programs - The stock dividend is a way for the company to share its recent clinical progress and optimism with shareholders, emphasizing its commitment to creating value while advancing its innovative pipeline of therapies [3]. - IMUNON is focused on developing transformative treatments, including its lead program IMNN-001 for advanced ovarian cancer, which has shown promising Phase 2 clinical data and is currently in a Phase 3 pivotal trial [3][5]. Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company that develops innovative treatments utilizing non-viral DNA technology, with a focus on solid tumors and immunological responses [4]. - The lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, instructing the body to produce cancer-fighting molecules at the tumor site [5].